{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:45:07Z","timestamp":1792014307008,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":825,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The Fracture Risk Assessment Tool (FRAX\u00ae) was created to predict major osteoporotic fractures (MOF) and hip fractures in the general population. Whether FRAX accurately predicts fractures in men with prostate cancer is unknown. Our objective was to assess the performance of FRAX for predicting incident fractures in men with prostate cancer. Men from the Manitoba Bone Mineral Density (BMD) Registry (1996\u20132018) with prostate cancer diagnoses in the 3\u2009years prior to dual-energy X-ray absorptiometry (DXA) were identified. FRAX scores with and without BMD were calculated. From population-based healthcare data we identified incident MOF, hip fracture, any osteoporotic fracture and death from the date of BMD testing to March 31, 2018. Cox regression was performed to estimate hazard ratios (HRs) with 95% confidence intervals (95% CIs) per standard deviation increase in FRAX score. Observed 10-year probability (estimated with competing risk of mortality) was compared with 10-year FRAX-predicted fracture probability to assess calibration. The study population included 684 men with prostate cancer (mean age 74.6\u2009years) and 8608 men without prostate cancer (mean age 65.5\u2009years). FRAX stratified risk for MOF (HR 1.91, 95% CI 1.48\u20132.45 with BMD; HR 1.96, 95% CI 1.43\u20132.69 without BMD) and hip fracture (HR 3.37, 95% CI 1.90\u20136.01 with BMD; HR 4.58, 95% CI 2.17\u20139.67 without BMD) in men with prostate cancer. There was no effect modification observed with prostate cancer status or current androgen deprivation therapy. Observed 10-year fracture probability in men with prostate cancer showed good agreement with FRAX with and without BMD included in the calculation (observed\/predicted calibration ratios MOF 0.97, hip 1.00 with BMD; MOF 0.92, hip 0.93 with BMD). In conclusion, FRAX reliably predicts incident fractures in men with prostate cancer. \u00a9 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4793","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T10:23:40Z","timestamp":1676888620000},"page":"659-664","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-5398","authenticated-orcid":false,"given":"Carrie","family":"Ye","sequence":"first","affiliation":[{"name":"University of Alberta Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-492X","authenticated-orcid":false,"given":"Suzanne N.","family":"Morin","sequence":"additional","affiliation":[{"name":"McGill University Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8685-3212","authenticated-orcid":false,"given":"Lisa M.","family":"Lix","sequence":"additional","affiliation":[{"name":"University of Manitoba Winnipeg Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8140","authenticated-orcid":false,"given":"Eugene V.","family":"McCloskey","sequence":"additional","affiliation":[{"name":"MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, Department of Oncology & Metabolism University of Sheffield Sheffield UK"},{"name":"Centre for Metabolic Bone Diseases University of Sheffield Medical School Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Johansson","sequence":"additional","affiliation":[{"name":"Mary McKillop Institute for Health Research Australian Catholic University Melbourne Australia"},{"name":"Centre for Metabolic Bone Diseases University of Sheffield Medical School Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-2512","authenticated-orcid":false,"given":"Nicholas C.","family":"Harvey","sequence":"additional","affiliation":[{"name":"NIHR Southampton Biomedical Research Centre University of Southampton and University Hospital Southampton NHS Foundation Trust Southampton UK"},{"name":"MRC Lifecourse Epidemiology Centre University of Southampton Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[{"name":"Centre for Metabolic Bone Diseases University of Sheffield Medical School Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-1691","authenticated-orcid":false,"given":"William D.","family":"Leslie","sequence":"additional","affiliation":[{"name":"University of Manitoba Winnipeg Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"3","key":"2024012714104083300_jbmr4793-bib-0001","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"8","author":"Global Burden of Disease 2019 Cancer Collaboration","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"2024012714104083300_jbmr4793-bib-0002","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"2024012714104083300_jbmr4793-bib-0003","doi-asserted-by":"crossref","first-page":"652979","DOI":"10.3389\/fphar.2021.652979","article-title":"Risk of fracture during androgen deprivation therapy among patients with prostate cancer: a systematic review and meta-analysis of cohort studies","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"2024012714104083300_jbmr4793-bib-0004","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11657-018-0510-0","article-title":"A brief history of FRAX","volume":"13","author":"Kanis","year":"2018","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2024012714104083300_jbmr4793-bib-0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","article-title":"Advisory Board of the National Osteoporosis Guideline Group. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2016","journal-title":"Arch Osteoporos"},{"issue":"2","key":"2024012714104083300_jbmr4793-bib-0006","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-012-2051-5","article-title":"Competing mortality and fracture risk assessment","volume":"24","author":"Leslie","year":"2013","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024012714104083300_jbmr4793-bib-0007","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"issue":"15","key":"2024012714104083300_jbmr4793-bib-0008","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO Endorsement of a Cancer Care Ontario Guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024012714104083300_jbmr4793-bib-0009","volume-title":"Prostate Cancer: Diagnosis and Management. Clinical Guideline 131","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2019"},{"key":"2024012714104083300_jbmr4793-bib-0010","doi-asserted-by":"crossref","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"issue":"6","key":"2024012714104083300_jbmr4793-bib-0011","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clon.2017.01.007","article-title":"Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care - Cancer Care Ontario Clinical Practice Guideline","volume":"29","author":"Alibhai","year":"2017","journal-title":"Clin Oncol"},{"issue":"12","key":"2024012714104083300_jbmr4793-bib-0012","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"2024012714104083300_jbmr4793-bib-0013","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1385\/JCD:8:1:025","article-title":"Construction and validation of a population-based bone densitometry database","volume":"8","author":"Leslie","year":"2005","journal-title":"J Clin Densitom"},{"issue":"6 Suppl","key":"2024012714104083300_jbmr4793-bib-0014","first-page":"JS10","article-title":"Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system","volume":"37","author":"Roos","year":"1999","journal-title":"Med Care"},{"key":"2024012714104083300_jbmr4793-bib-0015","author":"Population report: Health"},{"issue":"11","key":"2024012714104083300_jbmr4793-bib-0016","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1345\/aph.18117","article-title":"Validation of an electronic, population-based prescription database","volume":"32","author":"Kozyrskyj","year":"1998","journal-title":"Ann Pharmacother"},{"key":"2024012714104083300_jbmr4793-bib-0017","volume-title":"Cancer Data Linkage in Manitoba: Expanding the Infrastructure for Research","author":"Lix","year":"2016"},{"key":"2024012714104083300_jbmr4793-bib-0018","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/1471-2458-12-301","article-title":"Osteoporosis-related fracture case definitions for population-based administrative data","volume":"12","author":"Lix","year":"2012","journal-title":"BMC Public Health"},{"key":"2024012714104083300_jbmr4793-bib-0019","author":"2019 ISCD Official Adult Positions","year":"2021"},{"issue":"5","key":"2024012714104083300_jbmr4793-bib-0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","article-title":"Updated data on proximal femur bone mineral levels of US adults","volume":"8","author":"Looker","year":"1998","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024012714104083300_jbmr4793-bib-0021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"issue":"3","key":"2024012714104083300_jbmr4793-bib-0022","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00198-010-1464-2","article-title":"Construction of a FRAX\u00ae model for the assessment of fracture probability in Canada and implications for treatment","volume":"22","author":"Leslie","year":"2011","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024012714104083300_jbmr4793-bib-0023","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00198-010-1465-1","article-title":"Fracture prediction and calibration of a Canadian FRAX\u00ae tool: a population-based report from CaMos","volume":"22","author":"Fraser","year":"2011","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024012714104083300_jbmr4793-bib-0024","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/jbmr.123","article-title":"Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration","volume":"25","author":"Leslie","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024012714104083300_jbmr4793-bib-0025","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/jbmr.3726","article-title":"Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study","volume":"34","author":"Leslie","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024012714104083300_jbmr4793-bib-0026","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bone.2008.05.003","article-title":"Incidence and risk factors for low trauma fractures in men with prostate cancer","volume":"43","author":"Ahlborg","year":"2008","journal-title":"Bone"},{"issue":"15_suppl","key":"2024012714104083300_jbmr4793-bib-0027","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1200\/jco.2009.27.15_suppl.9517","article-title":"Use of age and BMD to predict fracture risk in men on androgen deprivation therapy","volume":"27","author":"Lin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024012714104083300_jbmr4793-bib-0028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/1055-9965.EPI-08-0415","article-title":"The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) Study","volume":"18","author":"Farhat","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"2024012714104083300_jbmr4793-bib-0029","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","article-title":"Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications","volume":"111","author":"Shao","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"2024012714104083300_jbmr4793-bib-0030","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"2024012714104083300_jbmr4793-bib-0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/M16-2577","article-title":"Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis","volume":"167","author":"Alibhai","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4793","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/38\/5\/659\/55456348\/jbmr4793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/38\/5\/659\/55456348\/jbmr4793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:47:10Z","timestamp":1710326830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/38\/5\/659-664\/7500039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4793","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4793\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4793\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4793\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4793\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4793\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4793\/v2\/review2","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2022-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}